PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Prior COVID-19 infection reduces infection risk for up to 10 months

The risk of being infected with SARS-CoV-2, the virus that causes COVID-19, is substantially reduced for up to 10 months following a first infection, according to new findings from the Vivaldi study led by UCL researchers

2021-06-04
(Press-News.org) Under embargo until Thursday 3 June, 23:30 UK time / 18:30 US Eastern time Peer-reviewed observational study in people Prior Covid-19 infection reduces infection risk for up to 10 months The risk of being infected with SARS-CoV-2, the virus that causes Covid-19, is substantially reduced for up to 10 months following a first infection, according to new findings from the Vivaldi study led by UCL researchers. For the study, published in Lancet Healthy Longevity, researchers looked at rates of Covid-19 infections between October and February among more than 2,000 care home residents and staff, comparing those who had evidence of a previous infection up to 10 months earlier, as determined by antibody testing, with those who had not been previously infected. They found that residents with a previous infection were 85% less likely to be infected during this four-month period than residents who had never been infected, while staff with past infection were 60% less likely than staff who had not had the infection before. The researchers said this showed strong protection in both groups, but cautioned that the two percentages may not be directly comparable, as staff may have accessed testing outside the care home, leading to positive tests not being included in the study. Also, residents who tested positive for antibodies likely represented a particularly robust group, having survived the first wave of the pandemic. Lead author Dr Maria Krutikov (UCL Institute of Health Informatics) said: "It's really good news that natural infection protects against reinfection in this time period. The risk of being infected twice appears to be very low. "The fact that prior COVID-19 infection gives a high level of protection to care home residents is also reassuring, given past concerns that these individuals might have less robust immune responses associated with increasing age. These findings are particularly important as this vulnerable group has not been the focus of much research." For the study, 682 residents (with a median age of 86) and 1,429 staff in 100 care homes in England underwent antibody blood tests in June and July last year following the first wave of Covid-19. About a third tested positive for antibodies, suggesting they had previously been infected. Researchers then analysed the results of participants' PCR tests, starting approximately 90 days after the blood samples were taken to ensure the tests did not pick up the initial infection. PCR tests were taken once a week for staff, and once a month for residents, with further testing in the event of an outbreak. Positive test results were only included if they were more than 90 days apart to make sure that the same infection was not included more than once. The number of staff and residents who were reinfected between October and February was very small. Based on the antibody test results, out of the 634 people who had been previously infected, reinfections occurred in only four residents and 10 members of staff. Among the 1,477 participants who had never been infected, positive PCR tests occurred in 93 residents and 111 staff. The study excluded the impact of vaccination by removing participants from the analysis 12 days following their first vaccination dose. The authors are addressing the question of vaccine effectiveness in a separate VivaIdi study. Senior author Dr Laura Shallcross (UCL Institute of Health Informatics) said: "This was a unique opportunity to look at the protective effect of natural infection in this cohort ahead of the roll-out of vaccination. "An important next step is to investigate the duration of immunity following natural infection and vaccination and to assess whether this protective effect is maintained against current and emerging variants. "We would like to thank all those staff and residents who volunteered their time and willingly gave their blood for antibody testing as well as Four Seasons Healthcare, whose collaboration with researchers made this possible."

INFORMATION:

The research was part of the UCL-led Vivaldi study looking at Covid-19 infections in care homes. It was funded by the Department of Health and Social Care and involved researchers at the University of Birmingham, Public Health England, Palantir Technologies UK and Four Seasons Healthcare Group.



ELSE PRESS RELEASES FROM THIS DATE:

Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant

2021-06-04
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet. The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn. ...

Immunotherapy drug delays recurrence in kidney cancer patients

Immunotherapy drug delays recurrence in kidney cancer patients
2021-06-04
An immunotherapy drug given after surgery improved disease-free survival rates in patients with kidney cancer at high risk of relapse. Interim results of a phase 3 trial of adjuvant therapy revealed a 32% decrease in the risk of recurrence or death with pembrolizumab compared with a placebo This is the first positive study of immunotherapy in patients with kidney cancer at high risk of relapse. BOSTON -- Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim ...

Genetic base editing treats sickle cell disease in mice

2021-06-03
Sickle cell disease (SCD) is the most common deadly genetic disorder, affecting more than 300,000 newborns worldwide each year. It leads to chronic pain, organ failure, and early death in patients. A team led by researchers at the Broad Institute of MIT and Harvard and St. Jude Children's Research Hospital has now demonstrated a base editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This gene editing treatment rescued the disease symptoms in animal models, enabling the long-lasting production of healthy blood cells. The root of SCD is two mutated copies of the hemoglobin gene, HBB, which cause red ...

Secret shopper study sheds light on barriers to opioid treatment for women

Secret shopper study sheds light on barriers to opioid treatment for women
2021-06-03
After a 2020 Vanderbilt University Medical Center study showed women have a difficult time accessing treatment for opioid use disorder (OUD), investigators analyzed comments received from the study's participants to further shed light on barriers to care, which included everything from long on-hold times to difficult interactions with clinic receptionists during phone calls seeking appointments. A "secret shopper" study published in JAMA Network Open in 2020 used trained actors trying to get into treatment for opioid use disorder in 10 U.S. states. More than 10,000 unique "patients" were randomly assigned to be pregnant or non-pregnant and have private or Medicaid-based insurance to assess differences ...

Athletic competition after COVID

2021-06-03
MEMPHIS, Tenn. - Cardiovascular imaging demonstrated no evidence of myocardial injury or myocarditis in athletes after COVID-19 infection, according to a research letter published in Circulation by Le Bonheur Children's Hospital and the University of Tennessee Health Science Center cardiologists. The screening and evaluation was conducted by the Le Bonheur Children's Heart Institute Sports Cardiology team, Benjamin S. Hendrickson, MD, Ranjit R. Philip, MD, and Ryan E. Stephens, NP-C, MBA, and Le Bonheur Director of Cardiac MRI Jason N. Johnson, MD, MHS. Researchers say this study confirms existing recommendations ...

Mockingbird song decoded

Mockingbird song decoded
2021-06-03
The North American mockingbird is famous for its ability to imitate the song of other birds. But it doesn't just mimic its kindred species, it actually composes its own songs based on other birds' melodies. An interdisciplinary research team has now worked out how exactly the mockingbird constructs its imitations. The scientists determined that the birds follow similar musical rules as those found in human music, from Beethoven to Kendrick Lamar. The song of the mockingbird is so complex that to investigate it required a joint effort of experts from very different fields. Neuroscientist Tina Roeske of the Max Planck Institute for Empirical Aesthetics, field biologist Dave Gammon of Elon University, ...

The dream team: Scientists find drug duo that may cure COVID-19 together

The dream team: Scientists find drug duo that may cure COVID-19 together
2021-06-03
COVID-19 continues to claim lives across the world and is infecting millions more. Although several vaccines have recently become available, making significant strides towards preventing COVID-19, what about the treatment of those who already have the infection? Vaccines aren't 100% effective, highlighting the need--now more than ever--for effective antiviral therapeutics. Moreover, some people can't receive vaccines due to health issues, and new variants of SARS-CoV-2, the virus that causes COVID-19, that can penetrate vaccine-conferred immunity, are being reported, indicating that we need to think beyond prevention. Given this need, a team of researchers based in Japan, the US, and the UK launched a project to develop effective therapeutics. ...

New algorithm for modern quilting

New algorithm for modern quilting
2021-06-03
Stanford University computer science graduate student Mackenzie Leake has been quilting since age 10, but she never imagined the craft would be the focus of her doctoral dissertation. Included in that work is new prototype software that can facilitate pattern-making for a form of quilting called foundation paper piecing, which involves using a backing made of foundation paper to lay out and sew a quilted design. Developing a foundation paper piece quilt pattern - which looks similar to a paint-by-numbers outline - is often non-intuitive. There are few formal guidelines for patterning and those that ...

Cultural, belief system data can inform gray wolf recovery efforts in US

Cultural, belief system data can inform gray wolf recovery efforts in US
2021-06-03
Humans regularly exert a powerful influence on the survival and persistence of species, yet social-science information is used only sporadically in conservation decisions. Researchers at Colorado State University and The Ohio State University have created an index depicting the mix of social values among people across all 50 states, providing data that can be useful for wildlife conservation policy and management. As a specific illustration, the research team found a supportive social context for gray wolf reintroduction in Colorado. Last fall, citizens ...

Immunotherapy after bladder cancer surgery may reduce recurrence, study shows

2021-06-03
NEW YORK CITY, June 2, 2021 -- New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in the New England Journal of Medicine. In this phase III randomized study, Dr. Bajorin and a team of investigators evaluated 709 patients who were at high risk for recurrence of urothelial cancer after removal of their bladder, ureter, or kidney for high-grade cancer. To evaluate for benefit, patients were randomized to receive either nivolumab or a placebo every two weeks for one year. Patients and ...

LAST 30 PRESS RELEASES:

Predicting risk in children with heart defects

Test performance improves when children can exercise briefly beforehand, UNCG researchers find

Meet IDEA: An AI assistant to help geoscientists explore Earth and beyond

Ready for market: New process boosts clean, cost-efficient chemical production

Losing weight before IVF may increase chance of pregnancy

New study uncovers how genetics and lifestyle drive the heart disease dilated cardiomyopathy

City of Hope study shows childhood cancer survivors face new health problems later in life

An innovative system that dehydrates fruit without heat

The Optica Foundation names Cara Green Executive Director of Development

Is the 'love hormone,' oxytocin, also the 'friendship hormone'?

Global Virus Network reaffirms support for mRNA vaccines and collaborative vaccine research

Unpacking chaos to protect your morning coffee

Planets without water could still produce certain liquids, a new study finds

Researchers identify key biomarkers for chronic fatigue syndrome

Surprisingly diverse innovations led to dramatically cheaper solar panels

Lab-made sugar-coated particle blocks Covid-19 infection — Possible new treatment on the horizon

Rice’s dean of engineering and computing building new software infrastructure for evolutionary biology

Researchers discover all-new antifungal drug candidate in McMaster’s greenhouse

New quality control for ‘wonder material’ graphene oxide is cheapest and fastest yet

How organic matter traps water in soil — even in the driest conditions

Cancer center taps UTA expert for survivor health study

Big gains in type 1 diabetes glucose-control management in recent years

Researchers unlock safer RNA therapies for inflammatory diseases

New gene linked to aggressive, treatment-resistant prostate cancer

Why oxytocin treatments for social behavior are inconsistent

The ISSCR releases targeted update to the guidelines for stem cell research and clinical translation

In utero brain surgery for Vein of Galen Malformation shows continued promise in new JAMA report

Dollar stores’ food options may not be hurting American diets overall

Georgia and Ukraine launch national Reproducibility Networks with support from the TIER2 project

Under-the-skin electrode allows for real-world epilepsy tracking

[Press-News.org] Prior COVID-19 infection reduces infection risk for up to 10 months
The risk of being infected with SARS-CoV-2, the virus that causes COVID-19, is substantially reduced for up to 10 months following a first infection, according to new findings from the Vivaldi study led by UCL researchers